Core Insights - The Shanghai Biopharmaceutical Innovation Achievements Exhibition showcases the progress made during the "14th Five-Year Plan" period, emphasizing innovation-driven development and reform in the biopharmaceutical sector [1][2]. Group 1: Innovation and Achievements - Shanghai has approved a total of 30 domestic Class 1 innovative drugs and 45 domestic Class 3 innovative medical devices from 2021 to September 2025, demonstrating its leading position in drug and device innovation in China [2]. - The number of overseas licensing transactions (License-out) from Shanghai reached 38 in 2024, accounting for 35% of the national total, with transaction amounts reaching $30.7 billion, representing 47% of the national total [2]. - Shanghai's research output in top-tier journals has increased significantly, with 3 out of 12 papers in the "Best of Cell 2024" list published by Shanghai researchers, and a total of 127 papers published in four major medical journals from 2021 to 2024 [3]. Group 2: Policy and Reform - The exhibition highlights 14 policy regulations and special measures introduced during the "14th Five-Year Plan" to promote high-quality development in the biopharmaceutical sector, covering areas such as drug regulation, medical device innovation, and clinical trials [5]. - New policies, including the "Opinions on Supporting the Full-Chain Innovation Development of the Biopharmaceutical Industry," aim to enhance the policy framework and support for the biopharmaceutical sector [5]. Group 3: Industry Growth and Structure - The biopharmaceutical industry in Shanghai has grown from ¥761.71 billion in 2021 to ¥984.70 billion in 2024, with a compound annual growth rate of 8.94%, and is expected to exceed ¥1 trillion in 2025 [6]. - By the end of 2024, Shanghai had 2,183 biopharmaceutical enterprises, including 675 manufacturing, 569 service, and 939 wholesale enterprises, indicating a robust industry structure [6]. - Major multinational pharmaceutical companies have established headquarters or R&D centers in Shanghai, with 19 out of the top 20 global pharmaceutical and medical device companies present [6]. Group 4: Financial Support and Investment - Shanghai's biopharmaceutical companies have been active in IPOs, with 102 companies listed across A-shares, Hong Kong, and the US, and several more in the pipeline [7]. - The Shanghai State Investment Corporation established a biopharmaceutical industry mother fund with a total scale of ¥22.5 billion to support the development of the biopharmaceutical innovation ecosystem [7].

Core Viewpoint - The article highlights the achievements and developments in Shanghai's biopharmaceutical industry during the "14th Five-Year Plan" period, emphasizing innovation, reform, and the establishment of a comprehensive ecosystem for biopharmaceutical innovation [1][3][9]. Group 1: Innovation Achievements - Shanghai has approved a total of 30 domestic Class 1 innovative drugs and 45 domestic Class 3 innovative medical devices from 2021 to September 2025, showcasing its leading position in drug and device innovation in China [3]. - The number of overseas licensing transactions (License-out) from Shanghai reached 38 in 2024, accounting for 35% of the national total, with a transaction value of $30.7 billion, representing 47% of the national total [3]. - Research output from Shanghai has significantly increased, with 3 out of 12 papers listed in "Best of Cell 2024" published by Shanghai researchers, and the number of papers in top global medical journals rising from 24 in 2021 to 52 in 2024, totaling 127 [4]. Group 2: Policy and Reform - Shanghai has implemented a series of policies aimed at addressing bottlenecks in the biopharmaceutical sector, including 14 policy regulations covering various key areas such as drug regulation, medical device innovation, and commercialization of innovative drugs [8]. - The exhibition highlighted new policies such as the "Opinions on Supporting the Full Chain Innovation Development of the Biopharmaceutical Industry" and the "Action Plan for Promoting the Full Chain Development of High-end Medical Devices" [8]. Group 3: Industry Growth - The biopharmaceutical industry in Shanghai has expanded from 761.7 billion yuan in 2021 to 984.7 billion yuan in 2024, with an average annual growth rate of 8.94%, and is projected to exceed 1 trillion yuan in 2025 [9]. - By the end of 2024, there were 2,183 large-scale biopharmaceutical enterprises in Shanghai, including 675 manufacturing companies and 569 service companies [9]. - Major multinational pharmaceutical companies have established their headquarters or R&D centers in Shanghai, with 19 out of the top 20 global pharmaceutical and medical device companies present [9].